We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: 9 Meters Biopharma, Inc. is a rare, orphan and unmet needs focused GI company. It's advancing NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for Short Bowel Syndrome, a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom. 9 Meters Biopharma Inc., formerly known as Innovate Bioph, is based in Raleigh, United States.
- Recent NMTR Stock Price: $0.28
- Yearly Gain for NMTR stock: -78.98%
- Market Cap for NMTR stock: $75.14M
- P/E Ratio for NMTR stock: -1.732
Will NMTR's stock price go up? Is there an accurate NMTR stock forecast available?
TipRanks.com reports that 9 Meters Biopharma currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $2.67. The target pricing ranges from a high NMTR forecast of $4.00 down to a low forecast of $1.00. 9 Meters Biopharma (NMTR)’s last closing stock price was $0.28 which would put the average price target at 865.29% upside.
In addition, TradingView issued a Strong Sell rating for NMTR stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on NMTR stock.
Other analysts covering NMTR include:
- Kumaraguru Raja of Brookline Capital Markets issued a Buy rating with the price target of $ 4 on 1 day ago
- Naz Rahman of Maxim Group issued a Buy rating with the price target of $ 1 on 1 day ago
- Tim Lugo of William Blair issued a Buy rating with the price target of n/a on 2 months ago
- Kevin DeGeeter of Oppenheimer issued a Buy rating with the price target of $ 5 on 7 months ago
If you are wondering if NMTR is a good stock to buy, here are 3rd party ratings for NMTR stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Top 43% (108 out of 251)
What is the sentiment on the street regarding 9 Meters Biopharma? (Current ratings compiled by TipRanks.com)
- News Sentiment for NMTR stock: Very Bullish
- Blogger Consensus for NMTR stock: ―
- Media Buzz for NMTR stock: Very High
- Insider Signal for NMTR stock: Positive
- Investor Sentiment for NMTR stock: Negative
- Hedge Fund signal for NMTR stock: No Signal
The stock market is extremely volatile, and you need to do your own research on NMTR stock including scouring the social networks like NMTR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for NMTR stock chart >>
Summary: Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom.
- Recent VRNA Stock Price: $4
- Yearly Gain for VRNA stock: -40.86%
- Market Cap for VRNA stock: $232.42M
- P/E Ratio for VRNA stock: -3.9
Will VRNA's stock price go up? Is there an accurate VRNA stock forecast available?
TipRanks.com reports that Verona Pharma currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $21.50. The target pricing ranges from a high VRNA forecast of $25.00 down to a low forecast of $18.00. Verona Pharma (VRNA)’s last closing stock price was $4 which would put the average price target at 437.50% upside.
In addition, TradingView issued a Sell rating for VRNA stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on VRNA stock.
Other analysts covering VRNA include:
- Ram Selvaraju of H.C. Wainwright issued a Buy rating with the price target of $ 25 on 1 day ago
- Liana Moussatos of Wedbush issued a Buy rating with the price target of $ 18 on 5 days ago
- Edward Nash of Canaccord Genuity issued a Buy rating with the price target of $ 23 on 7 months ago
- Thomas Shrader of BTIG issued a Buy rating with the price target of $ 17 on 7 months ago
If you are wondering if VRNA is a good stock to buy, here are 3rd party ratings for VRNA stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Top 43% (108 out of 251)
What is the sentiment on the street regarding Verona Pharma? (Current ratings compiled by TipRanks.com)
- News Sentiment for VRNA stock: Very Bullish
- Blogger Consensus for VRNA stock: Bullish
- Media Buzz for VRNA stock: Medium
- Insider Signal for VRNA stock: Negative
- Investor Sentiment for VRNA stock: Very Negative
- Hedge Fund signal for VRNA stock: Neutral
The stock market is extremely volatile, and you need to do your own research on VRNA stock including scouring the social networks like VRNA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for VRNA stock chart >>
Summary: DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of DexCom's monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. The company's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels.
- Recent DXCM Stock Price: $72.21
- Yearly Gain for DXCM stock: -34.08%
- Market Cap for DXCM stock: $27.66B
- P/E Ratio for DXCM stock: 136.101
Will DXCM's stock price go up? Is there an accurate DXCM stock forecast available?
TipRanks.com reports that Dexcom currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $119.95. The target pricing ranges from a high DXCM forecast of $140.00 down to a low forecast of $87.00. Dexcom (DXCM)’s last closing stock price was $72.21 which would put the average price target at 66.11% upside.
In addition, TradingView issued a Sell rating for DXCM stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on DXCM stock.
Other analysts covering DXCM include:
- Mathew Blackman of Stifel Nicolaus issued a Buy rating with the price target of $ 119 on 2 days ago
- James Mainwaring of Atlantic Equities issued a Buy rating with the price target of $ 125 on 6 days ago
- Cecilia Furlong of Morgan Stanley issued a Hold rating with the price target of $ 90.75 on 1 week ago
- Marie Thibault of BTIG issued a Buy rating with the price target of $ 135 on 3 weeks ago
If you are wondering if DXCM is a good stock to buy, here are 3rd party ratings for DXCM stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 30% (176 out of 251)
What is the sentiment on the street regarding Dexcom? (Current ratings compiled by TipRanks.com)
- News Sentiment for DXCM stock: Very Bullish
- Blogger Consensus for DXCM stock: Bullish
- Media Buzz for DXCM stock: Medium
- Insider Signal for DXCM stock: ―
- Investor Sentiment for DXCM stock: Positive
- Hedge Fund signal for DXCM stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on DXCM stock including scouring the social networks like DXCM StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for DXCM stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
